

1 Liver Shape Analysis using Statistical 2 Parametric Maps at Population Scale

3 Marjola Thanaj^{1*}, Nicolas Bastay¹, Madeleine Cule², Elena P Sorokin², Brandon Witcher¹,
4 Jimmy D Bell¹, E Louise Thomas¹

5 1 Research Centre for Optimal Health, School of Life Sciences, University of Westminster,
6 London, United Kingdom,

7 2 Calico Life Sciences LLC, South San Francisco, CA, United States

8

9 *Corresponding Author: *m.thanaj@westminster.ac.uk*

10

11 **Abstract**

12 **Background:** Morphometric image analysis enables the quantification of differences in the
13 shape and size of organs between individuals.

14 **Methods:** Here we have applied morphometric methods to the study of the liver by
15 constructing surface meshes from liver segmentations from abdominal MRI images in 33,434
16 participants in the UK Biobank. Based on these three dimensional mesh vertices, we
17 evaluated local shape variations and modelled their association with anthropometric,
18 phenotypic and clinical conditions, including liver disease and type-2 diabetes.

19 **Results:** We found that age, body mass index, hepatic fat and iron content, as well as, health
20 traits were significantly associated with regional liver shape and size. Interaction models in
21 groups with specific clinical conditions showed that the presence of type-2 diabetes
22 accelerates age-related changes in the liver, while presence of liver fat further increased
23 shape variations in both type-2 diabetes and liver disease.

24 **Conclusions:** The results suggest that this novel approach may greatly benefit studies aiming

25 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
at better categorisation of pathologies associated with acute and chronic clinical conditions.

26

27 **Key Words:** Magnetic Resonance Imaging, Liver Volume, Surface mesh, Image Analysis, 3D
28 mesh-derived phenotype, Statistical Parametric Maps, Type-2 Diabetes.

29

30 **Abbreviations:** T2D: Type 2 Diabetes; BMI: Body mass index; WHR: waist-to-hip ratio;
31 AST:ALT: ratio of aspartate aminotransferase to alanine aminotransferase; FIB-4: Fibrosis-4
32 index; Liver PDFF: Liver percentage density fat fraction; MUR : Mass univariate regression;
33 TFCE: Threshold-free cluster enhancement; SPMs: Statistical parametric maps; S2S:
34 Surface-to-surface.

35

36 **Introduction**

37

38 Despite improvements in global health [1], incidence of liver disease continues to rise,
39 with deaths due to hepatic conditions increasing by 400% since the 1970s (British Liver Trust
40 - <https://britishlivertrust.org.uk/>), making it the leading cause of death in those aged 35-49
41 years in the UK (ONS 2019 - <https://www.ons.gov.uk/>). Significant progress has been made
42 in recent years in the use of non-invasive imaging methods to measure the pathological
43 changes that are features of increasingly common liver conditions. This includes non-alcoholic
44 fatty liver disease (NAFLD) [2, 3], fibro-inflammation [4, 5] and fibrosis [6]. The prevalence of
45 these conditions, associated with obesity, insulin resistance and type-2 diabetes (T2D), are
46 likely only to increase further given the current obesogenic environment. New approaches are
47 needed to differentiate between those with mild disease, compared with those at risk of more
48 significant conditions (cirrhosis/end stage liver disease), and particularly those who may
49 experience accelerated disease processes [7]. One potential approach to address these
50 issues is the implementation of novel morphometric methods to gain a deeper understanding
51 of the processes underpinning the development and progression of many clinical conditions
52 [8]. For instance, investigating whether changes beyond simple volume or fat measurements,
53 such as liver shape, are associated with particular environmental risk factors, or whether they

54 can be differentially related to the aetiology of a particular condition. These methods may
55 potentially provide insight into different mechanisms of disease development and enable
56 optimised treatment strategies to be developed.

57

58 Automated segmentation of the liver to produce image-derived phenotypes (IDPs)
59 such as volume or fat deposition measurements are becoming more commonplace at scale
60 as deep learning methods gain traction [9]. While these methods enhance our understanding
61 of the liver at a population level, they are limited when it comes to providing additional
62 knowledge regarding morphological, functional and regional variation in response to a
63 particular condition.

64

65 Mapping organ segmentations to a standardised three-dimensional (3D) surface
66 mesh, enables many thousands of measurements relating to variation in organ shape to be
67 performed using statistical parametric maps (SPMs). A similar widely applied technique is
68 statistical shape analysis, which transforms the 3D surface mesh measurements into a smaller
69 number of principal components, known as shape parameters, has been used to characterise
70 variations in organ shape across a population. These approaches have been successfully
71 applied in neuroimaging [10, 11], abdominal computer tomography (CT) images [12, 13], and
72 cardiac imaging [14, 15] and they have shown to be useful in identifying genetic interactions
73 with cardiac pathology [16] and brain ageing [17]. However, they have been less frequently
74 applied to abdominal organs, where morphological changes are known to take place in a
75 variety of clinical conditions [18, 19].

76

77 In the current study we have applied SPM methods to determine morphological
78 variations in the liver and their potential association with anthropometric traits and clinical
79 conditions. We further investigated whether the emerging 3D liver mesh-derived phenotype
80 can add value to the prediction of disease outcomes. Our study made three main contributions.
81 The first contribution is that we investigate the impact of the population size and the robustness

82 of the liver template construction. Specifically, we investigated how the template image and
83 statistical parametric mapping are affected, providing valuable insights into determining the
84 optimal number of subjects for the liver template to represent the broader cohort. We also
85 examined the relevance of different participant samples in the template construction process.
86 The second contribution and also a novelty of our work is that we extend the SPM method to
87 the domain of liver image analysis. Here, we delve deeper into the application of SPM in liver
88 image analysis and applied it to the UK Biobank dataset, which comprises a large-scale
89 population-based cohort, resulting in increased statistical power. Through the linear
90 regression model, we examined the impact of anthropometric, phenotypic and clinical
91 conditions on regional geometry of the liver and visualised these findings on the template
92 surface mesh. The third contribution is that we extracted shape features derived from the 3D
93 mesh-derived phenotype by dimensionality reduction and evaluated whether these shape
94 features were better predictors of disease outcomes than the conventional measurement of
95 liver volume.

96 **Methods**

97

98 *Data*

99 The UK Biobank [20] is a population-based study in which 500,000 participants aged
100 40 to 70 years were recruited for deep phenotypic profiling. There is also a currently ongoing
101 imaging sub-study, in which 100,000 of the participants have been recruited to undergo an
102 imaging protocol including MRI of the brain, the heart, and the abdominal region. The
103 abdominal scans include a neck-to-knee Dixon 3D acquisition that can be used to derive
104 volumes of adipose tissue, skeletal muscle and abdominal organs. Full details regarding the
105 UK Biobank abdominal acquisition protocol have previously been reported [21]. We processed
106 and segmented the data using our automated methods [9]. In this study on liver morphology,
107 we included 41,800 participants with Dixon MRI data acquired at the imaging visit, between
108 2014 and 2020 with data comprising imaging, health-related diagnoses and biological
109 measurements.

110

111 Fully anonymized participant data was obtained through UK Biobank Access
112 Application number 44584. The UK Biobank has approval from the North West Multi-Centre
113 Research Ethics Committee (REC reference: 11/NW/0382) written informed consent was
114 obtained from all participants prior to inclusion in the UK Biobank.

115

116 *Phenotype Definitions*

117 Anthropometric measurements including age, body mass index (BMI), waist and hip
118 circumferences were taken at the UK Biobank imaging visit and ethnicity was defined based
119 on the continental genetic ancestry (<https://pan.ukbb.broadinstitute.org>). AST:ALT ratio,
120 defined as the ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT),
121 commonly used to indicate presence of more advanced liver disease including fibrosis and
122 cirrhosis [22, 23] was calculated from the biological samples taken at the initial assessment
123 visit. The fibrosis-4 index (FIB-4), also designed to identify more advanced stages of liver

124 disease and fibrosis in particular, was calculated as previously described [24] using age, AST,
125 ALT and platelet count taken from the initial assessment visit. Diagnosis of liver disease and
126 T2D was obtained from UK Biobank hospital records and self-reported information (see
127 Disease Categories in supporting information). Due to the relatively limited number of scanned
128 participants within the UKBB diagnosed with specific liver diseases, a broad umbrella definition
129 of liver disease was implemented which included, alcoholic liver disease, fibrosis, cirrhosis,
130 and chronic hepatitis.

131

132 *Quality Control*

133 We included liver segmentations from an overall 41,800 participants. For details on the
134 segmentation process and quality control refer to the supplementary data in [9]. Participants
135 with missing clinical, anthropometric or biochemical data, as well as those with Dixon MRI
136 datasets that did not have full anatomical coverage were excluded from the study, including
137 organs with zero volume. More specifically, we removed 8,297 data that were missing
138 ethnicity, BMI, WHR, AST, ALT, platelet count and liver IDPs. We also conducted quality
139 control measures to determine potential extreme values in the liver volume and ensure the full
140 anatomical coverage of the organs by visually examining values falling outside from randomly
141 selected quantiles (0.1% and 99.9%) and excluding eight outliers. We visually inspected
142 segmentations with 3D liver mesh-derived values to potentially identify extremely high values,
143 resulting in the exclusion of 61 datasets with segmentation errors. Overall, from the initial
144 41,800 participants, 33,434 participants were included in the final analysis (20% of data
145 excluded).

146

147 *Study Design*

148 *Template Definition*

149 Deformation of an image to a standard organ template is a key part of MRI organ shape
150 assessment. Given the potential variation in morphology, it is important to identify a suitable
151 population sample size for constructing a template image [25]. To assess the impact of

152 population size on template construction, we constructed three distinct templates using liver
153 segmentations from a gender-balanced European ancestry cohort of 20, 100 and 200
154 participants with BMI < 25 kg/m² and low liver fat (< 5%). The characteristics for each template
155 population are provided in Supplementary Table S1. To test the 3 templates, we selected 500
156 participants, derived from the full cohort, with European genetic ancestry, aged between 46
157 and 62 years old, without any disease reported or diagnosed here [26] (Supplementary Table
158 S2). We then registered the three liver templates to the 500-participant cohort and investigated
159 the associations between the 3D mesh-derived phenotype and the anthropometric covariates
160 across the three templates.

161

162 *Association between mesh-derived phenotypes, IDPs and Disease*

163 To assess the associations between the 3D mesh-derived phenotype, the
164 anthropometric covariates and liver IDPs (volume, fat, iron), we first analysed the liver MRI
165 data from the entire UK Biobank imaging cohort. The cohort of 33,434 participants was 97.6%
166 European, 48.7% male and aged between 44 and 82 years old (Supplementary Table S3). To
167 determine the potential association between disease and liver shape, we first selected
168 diseases that are known from previous studies to impact liver health, and are associated with
169 changes in liver fat accumulation or volume [9]. These included 449 participants with liver
170 disease (207F/242M; 48-81 years old; BMI 18.6-43.8 kg/m²) and 1,780 participants with T2D
171 (67% males; 46-82 years old; BMI 18.3-50.1 kg/m²) (Supplementary Table S4).

172

173 *Prediction of disease outcomes*

174 To determine whether the 3D mesh-derived phenotype was a better predictor of
175 disease outcomes than the conventional measurement of liver volume, we identified 182
176 participants with liver disease (45% males; 45-78 years old; BMI 16.5-46.1 kg/m²) and 144
177 participants with T2D (61% males; 45-80 years old; BMI 19.9-47.9 kg/m²) that were diagnosed
178 after the baseline imaging visit (see supporting information). We then identified a control cohort
179 without any reported conditions and designed a case-control study for each disease

180 population, achieving a 364 case-control cohort with liver disease and 288 case-control cohort
181 with T2D. The control cohort was chosen by matching one individual with every case by age
182 (± 1 year), gender and BMI (± 2 kg/m²) using the R package *ccoptimalmatch* [27].

183

184 *Image Registration and Mesh Construction*

185 The process for template construction of the liver has been previously described [28].
186 Here, we constructed three distinct templates using liver segmentations from 20, 100 and 200
187 subject-specific volumes in order to evaluate the impact of cohort size on template
188 construction. It also allows us to test if cohort size influenced the statistical associations in our
189 mesh-based analysis. We constructed surface meshes from each template using the
190 marching cubes algorithm and smoothed using a Laplacian filter [29]. The template
191 construction was performed using ANTs software (<https://picsl.upenn.edu/software/ants>) with
192 mutual information as the similarity metric and the B-spline non-rigid transformation. Briefly
193 the process of the template construction is performed in two stages: affine registration to
194 account for translation, rotation, scaling and shearing, and non-rigid registration to account for
195 local deformation using the symmetric image normalisation (SyN) method with mutual
196 information as the similarity metric [30, 31]. The analysis was performed using
197 “antsMultivariateTemplateConstruction2.sh” script provided from ANTs, with the following
198 default parameters: -i (iteration limit) = 4, -g (gradient step size) = 0.25, -k (number of
199 modalities) = 1, -w (modality weight) = 1. The rest parameters were customised depending on
200 the machine used, image dimension and the metrics applied, including: -d (image dimension)
201 = 3, -j (number of CPU cores) = 10, -c (control for parallel computation) = 2, -q (max iteration
202 for each pairwise registration) = 100x70x50x10, -n (NBiasFieldCorrection of moving image) =
203 0, -r (do rigid body registration of inputs to the initial template) = 1, -m (similarity metric) = MI
204 and -t (transformation model) = BSplineSyN.

205

206 Surface meshes were first constructed from each subject’s segmentations using
207 marching cubes algorithm and smoothed using a Laplacian filter. Then the template-to-subject

208 registration was performed by first applying rigid registration to remove the position and
209 orientation difference between all subject-specific surfaces and template surfaces and an
210 affine transformation with nearest neighbour interpolation was computed between template
211 and subject segmentations. The resulting affine transformations were used to warp the
212 template to the subject's space. The template segmentation is then mapped into each subject
213 segmentation by computing a non-rigid transformation modelled by a free-form deformation,
214 based on B-Splines, with label consistency as the similarity metric between the subject and
215 template liver segmentations [32]. To enable subject comparison with vertex-to-vertex
216 correspondence, the template mesh is then warped to each subject mesh using the
217 deformation fields obtained from the non-rigid registration. Hence, all surface meshes are
218 parameterised with the same number of vertices (approximately 18,000). This ensures that
219 each vertex maintains approximate anatomical accuracy and consistency across all subjects,
220 while preserving the size and shape information for subsequent analyses [29].

221

222 To determine the regional outward or inward adaptations in the liver surface in
223 comparison to an average liver shape, the surface-to-surface (S2S) distance, a 3D mesh-
224 derived phenotype for each subject was measured. This was achieved by computing the
225 signed distance between each vertex in the template mesh and each corresponding vertex in
226 the subjects' mesh. This indicates positive distances for outward expansion in the subject's
227 vertices compared to template vertices and negative distances for inward shrinkage in the
228 subject's vertices. All the steps for the template-to-subject registration were performed using
229 the Image Registration Toolkit (IRTK) (<https://biomedica.doc.ic.ac.uk/software/irtk>). After
230 conducting the described manual quality control process, which involved identifying extremely
231 high S2S values, we found that all the values fell within the range of -48.3 to 70.5 mm. This is
232 to ensure that the organ sizes were within an expected range and to suggest that there were
233 no significant segmentation errors, such as the inclusion of surrounding tissues in the liver
234 segmentations.

235

236 *Mass Univariate Regression*

237 Associations between the S2S values and anthropometric variables were modelled
238 using a linear regression framework. To enhance the detection of spatially contiguous signals
239 and discriminate them from noise, we utilised threshold-free cluster enhancement (TFCE) [33].
240 TFCE not only provides improved sensitivity and stability compared to other cluster-based
241 techniques but also identifies local maxima in the resulting significance map that is not
242 possible in other enhancement and thresholding techniques [14, 33]. A permutation testing
243 was then performed on the TFCE maps and the derived TFCE p-values were corrected to
244 control the false discovery rate (FDR), as previously described [28]. Specifically, we performed
245 mass univariate regression (MUR) analysis using the R package *mutools3D* [34] and adjusted
246 for multiple comparisons by applying the FDR procedure [35] to all the TFCE p-values derived
247 from each vertex using 1,000 permutations. The estimated regression coefficients $\hat{\beta}$ for each
248 of the relevant covariates and their related TFCE-derived p-values were then displayed at
249 each vertex in the mesh on the whole 3D liver anatomy, providing the spatially-distributed
250 associations. Regions of the liver exhibiting significant associations (p-values < 0.05) between
251 variables were identified, and the estimated regression coefficients $\hat{\beta}$ for each relevant
252 covariate within those regions were reported. The MUR model for deriving associations
253 between clinical parameters and a 3D phenotype is outlined in Supplementary Fig. S1.

254

255 To determine which factors influence the design and performance of the liver template,
256 we used a regression model to address: (1) how many participants are required to construct
257 a representative liver template, (2) whether the template population size affected the
258 associations between the S2S and the anthropometric covariates, (3) which factors have an
259 impact on regional S2S distances and (4) how are the changes in S2S distances linked to liver
260 disease and T2D.

261

262 We constructed three models adjusting for additional covariates. **Model 1** was
263 adjusted for age, gender, ethnicity, body mass index (BMI) and waist-to-hip ratio (WHR), liver
264 fat (referred to as proton density fat fraction (PDFF)) and liver iron concentration with
265 correction to control the FDR. To investigate the morphological changes related to liver
266 function **Model 2** had all the covariates from model 1 plus AST:ALT, FIB-4 index and disease
267 conditions. We further adjusted with interaction terms between age and disease status and
268 between liver fat and disease. In order to test whether there is a circadian effect in the liver
269 morphology, **Model 3** included all the covariates from model 2 plus time of the day for the MRI
270 scan, discretised into hours of the day.

271

272 *Predictive Model*

273 To determine whether S2S distance improves the prediction of disease outcomes
274 prospectively, we used a logistic regression model. This model allowed us to investigate the
275 associations between liver volume as well as the S2S values from the baseline imaging visit
276 and the occurrence of disease outcomes in two distinct case-control cohorts: one comprising
277 individuals with liver disease and the other with T2D.

278

279 Due to having a large number of S2S values for small population groups, we first
280 calculated the sparse principal component analysis (SPCA) using the R package *sparsepca*
281 [36] and extracted principal component scores representing the shape features of the S2S
282 distances for each disease case-control group that were diagnosed after the baseline imaging
283 visit. We utilised the principal component scores for each individual corresponding to the
284 modes that summarised 90% of the cumulative variation for each group. We then performed
285 this analysis in two models. In the first model (the volume model), the disease outcome was
286 regressed on age, gender, ethnicity, BMI, WHR, AST/ALT, FIB-4 index, liver volume, PDFF
287 and iron concentration. In the second model (the S2S model), we included all the covariates
288 from the volume model, adding the principal component scores of the S2S distances for each
289 disease group.

290

291 Predictive modelling was performed using the R package *caret* [37]. Model training
292 was conducted with leave-one-out cross validation for each group. Our model performance
293 was evaluated using several metrics, including the Area Under the Curve (AUC) of the
294 Receiver Operating Characteristic (ROC) curve, the F1 score, accuracy, and
295 sensitivity/specificity. Additionally, we employed Delong's test to compare the AUC of the ROC
296 curves from S2S and liver volume models [38].

297

298 **Results**

299

300 *Template Consistency*

301 We constructed three separate template meshes using gender-balanced cohorts of
302 20, 100 and 200 participants and computed the distances between each template mesh for
303 each subpopulation (Supplementary Fig. S2). The results showed that cohort size had little
304 impact on the shape of the template, with differences less than 8mm, especially for the
305 templates constructed using 100 participants compared with the 200-participant template.
306 More specifically, the median absolute distance between the 20-participant and 200-
307 participant templates was found to be -1.1 (IQR: 3.2) mm, whereas the median distance
308 between the 100-subject and 200-subject templates was even smaller (-0.4 (1.8) mm). To
309 further examine the relevance of different participant samples in the template construction
310 process, we constructed five templates, each constructed from different samples drawn from
311 a population of 20 participants each. The Dice coefficients of the template images for the 20-
312 participant template experiment consistently demonstrates a high level of overlap across the
313 distinct cohorts (Supplementary Table S5). It is important to note that when constructing
314 templates using larger cohort sizes (e.g., 100 or 200 participants), it is expected that the
315 variability will be reduced due to the averaging effect. Based on these findings, we are
316 confident in the robustness and consistency of our template construction process.

317

318 We further investigated for each template the associations between S2S distances and
 319 anthropometric variables, adjusting for the covariates in Model 1 to examine how the statistical
 320 parametric mapping is influenced across the three templates. We only looked at the
 321 associations between BMI and WHR with S2S distances, as only these variables exhibited
 322 statistically significant associations. Here we visually presented the 3D SPMs, with the TFCE
 323 corrected p-values, of BMI and WHR with the S2S distance on the 500-participant cohort
 324 (Supplementary Fig. S3) and presented the significance areas of their associations across the
 325 three templates (Table 1). By combining qualitative and quantitative assessments, we showed
 326 that the distribution of the corrected p-values were consistent across all three different
 327 templates and that there was no apparent difference in the areas of association between BMI
 328 and WHR with S2S distances across the three templates.
 329

Significance area	20-participant template		100-participant template		200-participant template	
	BMI	WHR	BMI	WHR	BMI	WHR
Total	58.08%	14.48%	55.20%	18.28%	56.73%	12.12%
$\hat{\beta} < 0$	2.74%	4.79%	3.28%	7.42%	2.66%	4.67%
$\hat{\beta} > 0$	55.34%	9.69%	51.92%	10.85%	54.07%	7.46%

330 **Table 1.** Significance areas from the association between BMI and WHR with S2S distances
 331 on a 500-participants cohort, in the MUR model using a template with 20, 100 and 200
 332 participants. The significance area is the percentage of vertices on the liver mesh where the
 333 regression coefficients are statistically significant ($p < 0.05$) after adjustment for multiple
 334 comparisons. The total area has been split into areas of negative ($\hat{\beta} < 0$) and positive ($\hat{\beta} > 0$)
 335 associations.

336
337
338
339
340
341
342
343
344
345
346

To test template consistency on a disease population, all three templates were registered on a cohort of 449 participants with liver disease and the 3D S2S phenotype computed between template and participants' surface. We then modelled the associations between the S2S distances and anthropometric variables adjusting for the covariates in model 1. The TFCE corrected p-value maps on the cohort with liver disease were consistent across the three templates, with little difference in the significance area for the association between BMI and S2S distances (97.58% using the 20-participant template, 97.46% using the 100-participant template and 96.43% using the 200-participant template) (Supplementary Fig. S4 and Table 2).

Significance area	20-participant template		100-participant template		200-participant template	
	BMI	WHR	BMI	WHR	BMI	WHR
Total	97.58%	91.02%	97.46%	90.31%	96.43%	90.98%
$\hat{\beta} < 0$	0.01%	0.01%	0%	0%	0%	0%
$\hat{\beta} > 0$	97.57%	91.01%	97.46%	90.31%	96.43%	90.98%

347 **Table 2.** Significance areas from the association between BMI and WHR with S2S distances
348 on a cohort with liver disease (N=449), in the MUR model using a template with 20, 100 and
349 200 participants. The significance area is the percentage of vertices on the liver mesh where
350 the regression coefficients are statistically significant ($p < 0.05$) after adjustment for multiple
351 comparisons. The total area has been split into areas of negative ($\hat{\beta} < 0$) and positive ($\hat{\beta} > 0$)
352 associations.
353

354 *Associations with Anthropometric Characteristics, Liver IDPs and Disease*

355 As the liver template was relatively insensitive to the number of participants included,
356 we performed all subsequent analyses using the 200-participant template. We proceeded to
357 register the template on the full cohort (N=33,434), computing S2S distances between the
358 template and surface of each individual liver mesh and performed MUR analysis adjusting for
359 the covariates in Model 2.

360

361 A summary of the model for the whole cohort, representing the regression coefficients
362 and the significance areas on the liver, is provided in Table 3 and Supplementary Fig. S5. The
363 SPMs that represent associations between S2S distances and the anthropometric
364 measurements and liver IDPs with units in standard deviations for each covariate, are shown
365 in Fig. 1.


366

367 Lower S2S distances were associated with greater age over 96.63% of the liver, with
368 a median change of -0.11 mm/year, while BMI and WHR had statistically significant positive
369 associations with S2S distances, covering 97.82% and 58.11% of the liver, respectively. The
370 AST:ALT ratio showed mostly statistically significant positive association with S2S distances
371 in the anterior part of the left lobe and the posterior part of the right lobe, with a median
372 difference of 0.30 mm (significance area = 48.05%). FIB-4 index on the other hand showed a
373 median S2S distance of -0.22 mm (significance area = 82.62%). Liver PDFF was positively
374 associated with S2S distances, showing median outward shape variations of 0.26 mm/%,
375 whereas liver iron concentration was associated with S2S distances of -0.59 mm/(mg/g) in the
376 anterior part of the right lobe and the posterior part of the left lobe and a median 0.34
377 mm/(mg/g) in the anterior part of the left and caudate lobe. Additionally, we included MRI scan
378 time as an additional covariate in the model since liver size is known to vary during the day
379 [9], but this had no apparent effect on any of the associations (Supplementary Table S6,
380 Supplementary Fig. S6).

381

382 A diagnosis of liver disease was associated with a median S2S of -2.13 mm when
383 compared to the controls (significance area = 21.90%) in the anterior part of the right lobe as
384 well as at the posterior part of left and right lobe and a median of 1.95 mm (significance area
385 = 25.14%) in the anterior part of the left lobe. T2D was positively associated with S2S
386 distances, with a median of 2.42 mm for participants with T2D covering a significance area of
387 86.40% of the liver. The time of day at which the MRI scan was conducted had no effect on
388 the associations between S2S and T2D, although we observed a reduction in the significance
389 area for the associations between S2S and liver disease (significance area = 28.34%,
390 Supplementary Table S6, Supplementary Fig. S6).

391



392

393 **Figure 1.** Three-dimensional statistical parametric maps (SPMs) of liver morphology, two
394 projections are shown for each SPM providing anterior (left) and posterior (right) views of the
395 liver. The SPMs show the local strength of association for each covariate in model 2 with S2S

396 distances on the full cohort (N=33,434). Yellow contour lines indicate the boundary between
 397 statistically significant regions ($p < 0.05$) after correction for multiple testing, with positive
 398 associations in red and negative associations in blue. Standardised regression coefficients
 399 are shown with units in standard deviations for each covariate. BMI: body mass index, WHR:
 400 waist-to-hip ratio, AST:ALT: aspartate aminotransferase/alanine aminotransferase ratio, FIB-
 401 4: Fibrosis-4 score, Liver PDFF: Liver percentage density fat fraction, T2D: type-2 diabetes.
 402


	$\hat{\beta} < 0$		$\hat{\beta} > 0$		Total
	Beta coefficients	Significance area	Beta coefficients	Significance area	Significance area
Age (yrs.)	-0.11 (0.06)	96.63%	0.02 (0.04)	1.46%	98.10%
BMI (kg/m^2)	-0.08 (0.07)	1.61%	0.30 (0.22)	97.82%	99.43%
WHR	-3.88 (4.02)	33.99%	3.87 (3.65)	58.11%	92.10%
AST:ALT	-0.32 (0.32)	35.17%	0.30 (0.29)	48.05%	83.22%
FIB-4	-0.22 (0.17)	82.62%	0.23 (0.13)	2.09%	84.70%
Liver PDFF (%)	-0.03 (0.02)	0.17%	0.26 (0.10)	99.65%	99.82%
Liver Iron (mg/g)	-0.59 (0.74)	58.00%	0.34 (0.32)	24.99%	82.98%
Liver disease	-2.13 (2.95)	21.90%	1.95 (2.43)	25.14%	47.05%
T2D	-0.61 (0.77)	5.35%	2.42 (1.94)	86.40%	91.76%
Age * Liver	ns	ns	ns	ns	ns

disease					
Liver PDFF *	-0.09 (0.01)	0.09%	0.09 (0.03)	12.59%	12.68%
Liver disease					
Age * T2D	-0.03 (0.02)	71.23%	0	0%	71.23%
Liver PDFF * T2D	-0.06 (0.04)	6.24%	0.10 (0.08)	82.84%	89.08%

403 **Table 3.** Significance areas for covariates in the MUR model between the anthropometric
404 covariates and liver IDPs (N=33,434) in model 2. The total area has been split into areas of
405 positive and negative associations. The regression coefficients are presented as median
406 (interquartile range - IQR) and the significance areas as a percentage (%) of the vertices.
407 Where BMI: body mass index, WHR: waist-to-hip ratio, AST:ALT: aspartate
408 aminotransferase/alanine aminotransferase ratio, FIB-4: Fibrosis-4 score, Liver PDFF: Liver
409 percentage density fat fraction, T2D: type-2 diabetes, ns: not significant.

410
411 We undertook further analysis to determine whether there was an interaction between
412 clinicalstate and factors such as age and liver PDFF adjusted for all covariates in Model 2.
413 Our results varied according to the disease of interest. While there were no significant
414 associations for the interaction between age and liver clinical condition, we found a median
415 association of -0.14 mm/year in T2D participants, compared with -0.11mm/year in non-T2D
416 participants, over a similar anatomical region. The interaction term between age and T2D in
417 this model was significantly different from zero, with a significance area = 71.23% (Table 3
418 and Fig. 1). The association between age and S2S distances in participants with and without
419 T2D are directly compared in Fig. 2, where participants diagnosed with T2D display
420 accelerated decreases in the anterior part of the left and right lobe as well as at the posterior
421 part of left and right lobe of the liver.

422




423

424 **Figure 2.** Three-dimensional statistical parametric maps (SPMs) of liver morphology,
425 projections are anterior (left) and posterior (right). The SPMs show the local rate of change as
426 a function of age for S2S distances in participants (i) without T2D versus those (ii) with T2D
427 on the full cohort (N=33,434). Positive associations are in red and negative associations in
428 blue. Standardised regression coefficients are shown with units in standard deviations.

429

430 The presence of liver PDFF in participants with liver disease resulted in an additional
431 median variation of 0.09 mm/% over an area 12.59% of the liver, in addition to the median
432 variation of 0.26 mm/% associated with the main effect of liver PDFF (Table 3 and Fig. 1).
433 Interestingly this effect was no longer significant after including scan-time as an additional
434 covariate in the model (Supplementary Table S6, Supplementary Fig. S6). A change of similar
435 magnitude, over a much larger proportion of the liver was observed for the interaction between
436 liver PDFF and T2D (Table 3 and Fig. 1). Here we observed an accelerated increase in S2S
437 distances with a median change of 0.10 mm/%, over the majority of the liver surface area
438 (significance area = 82.84%), in addition to the median increase of 0.26 mm/% for the main
439 effect of liver PDFF. The rates of change in S2S distances due to changes in liver PDFF for

440 participants with liver disease only, with T2D only and those without either disease are directly
441 compared in Fig. 3. The local variations associated with liver PDFF fluctuates significantly with
442 disease diagnosis. Participants diagnosed with liver disease (Fig. 3ii) display accelerated
443 increases in S2S distances in the anterior and posterior parts of the right lobe with increasing
444 liver PDFF, with slight decreases in the rate of change in both the anterior and posterior left
445 lobe when compared to participants without either liver disease or T2D. Participants with T2D
446 (Fig. 3iii) display accelerated increases in S2S distances in the anterior and posterior right
447 lobe and the posterior left lobe when compared to participants without T2D, and display
448 substantial decreases in the rate of change in S2S distances in the anterior left lobe when
449 compared to participants who have been diagnosed with liver disease but not T2D or
450 participants who have not been diagnosed with either liver disease or T2D.



451

452 **Figure 3.** Three-dimensional statistical parametric maps (SPMs) of liver morphology,
453 projections are anterior (left) and posterior (right). The SPMs show the rate of change as a
454 function of liver PDFF for S2S distances in participants (i) without liver disease or T2D, (ii) with
455 liver disease only and (iii) with T2D only on the full cohort (N=33,434). Positive associations
456 are in red and negative associations in blue. Standardised regression coefficients are shown
457 with units in standard deviations.

458

459 *Predictive Analysis*

460 We investigated whether S2S distances add value to disease prediction beyond those
461 obtained using liver volume. We compared the performance of two models; one including age,
462 gender, ethnicity, BMI, WHR, AST:ALT, FIB-4 index, liver PDFF, liver iron and liver volume
463 (the volume model); the other including age, gender, ethnicity, BMI, WHR, AST:ALT, FIB-4
464 index, liver PDFF, liver iron, liver volume and the principal component scores of the S2S
465 distances (the S2S model), for the liver disease (N=364) and T2D (N=288) case-control
466 cohorts. We found that the liver volume model achieved an AUC=0.57 and accuracy=0.54
467 (sensitivity/specificity=0.42/0.66) for liver disease prediction and AUC=0.64 and
468 accuracy=0.62 (sensitivity/specificity=0.54/0.70) for T2D prediction (Table 4). The first 40
469 modes of the SPCA were sufficient to describe over 90% of the S2S distances in both cohorts,
470 thus the first 40 scores in each cohort were used as independent variables in the model. The
471 S2S model improved the prediction of liver disease achieving an AUC of 0.61, accuracy of
472 0.59 and sensitivity/specificity values of 0.57/0.60. However, when comparing the S2S and
473 the volume models, the improvement was not statistically significant ($p=0.1$). Additionally,
474 there was no statistically significant improvement in T2D (AUC=0.64, accuracy=0.62,
475 sensitivity/specificity=0.59/0.64) compared to the model with liver volume.

476

477 Supplementary Fig. S7 shows the increase in AUC with the increasing numbers of
478 modes, from 1 until 40 for the prediction of liver disease and T2D. Notably, the S2S model for
479 liver disease prediction reached its peak performance when utilising 21 modes, resulting in an

480 AUC of 0.63 (95% confidence interval (CI): 0.57-0.69) and an F1 score of 0.64. This
 481 improvement was statistically significant (p=0.013), with an accuracy of 0.63 and
 482 sensitivity/specificity values of 0.60/0.65. Furthermore, we observed a slight enhancement in
 483 T2D prediction using the S2S model with 11 modes, resulting in an AUC of 0.67 (with 95% CI
 484 of 0.60 to 0.73) and an F1 score of 0.63. However, this improvement was not statistically
 485 significant (Supplementary Fig. S7).
 486

Case - Control Cohort	Models					
	Volume			S2S		
	AUC (95% CI)	F1 score	Accuracy (Sensitivity / Specificity)	AUC (95% CI)	F1 score	Accuracy (Sensitivity / Specificity)
Liver disease	0.57 (0.50- 0.62)	(0.59)	0.54 (0.42 / 0.66)	0.61 (0.55- 0.67)	(0.60)	0.59 (0.57 / 0.60)
T2D	0.64 (0.58- 0.71)	(0.65)	0.62 (0.54 / 0.70)	0.64 (0.57- 0.70)	(0.62)	0.62 (0.59 / 0.64)

487 **Table 4.** Predictive models trained with leave-one-out cross validation for both liver disease
 488 (N=364) and T2D (N=288) case-control groups. Each cell contains the area under the curve
 489 (AUC) with 95% confidence intervals (CI) in parentheses, F1 score and accuracy with
 490 sensitivity and specificity in parentheses.

491
 492 **Discussion**
 493

494 In this study, we mapped local shape variations across the liver and determined how
495 these changes were associated with anthropometric, phenotypic and health traits. To achieve
496 this we constructed surface meshes from liver segmentations of 33,434 participants from the
497 UK Biobank. Previous studies using similar SPMs have suggested that this is a useful
498 technique in neuroimaging [10] and cardiac imaging [14], enabling the associations between
499 phenotypic and genetic variation in specific anatomical regions to be mapped [16].

500

501 We constructed a representative liver template, and showed that a 200-participant
502 template was sufficient to represent the broader cohort. Indeed, the number of participants
503 included in the template construction did not impact the power of the statistical analysis across
504 a 500-participant test cohort, or a second cohort of 479 participants with liver disease. This is
505 in line with previous studies that found a cohort with 100 participants was sufficient to construct
506 a representative cardiac template to investigate the shape of the left ventricle [29].

507

508 Liver size has been explored extensively using a variety of approaches from autopsy
509 measurements [39], CT [40], ultrasound [41], and MRI [19], as well as regression-based
510 algorithms designed to predict liver size based on body surface area [42]. Given accurate
511 assessment of liver volume is essential for many aspects of hepatic surgery and determining
512 disease progression [43], suitable methods are needed. However, until recently, the manual
513 annotation required to make true volumetric measurements of the liver from CT and MRI
514 images has been extremely time consuming. Imaging studies tended to rely on more easily
515 measured metrics, such as liver span or diameter [44, 45], or calculation of volume indices
516 from the measurement of multiple diameters [46]. Consequently, these approaches limit in
517 depth morphometric assessment and only provide information associated with overall
518 changes to liver size or volume. The SPM method implemented in the current study
519 demonstrates significant regional variations in liver shape associated with anthropometric
520 variables and disease status, including simultaneous inwards and outwards adaptations.
521 These novel phenotypic variables may be useful in longitudinal population studies, as well as

522 determining trajectories of progression in aggressive clinical conditions, including monitoring
523 liver cirrhosis and hepatic oncology.

524

525 While studies of liver volume have generally focussed on patient populations, there is
526 increasing interest in understanding how hepatic volume and form is influenced by age,
527 anthropometry and metabolic markers in the wider population [9, 46]. Despite this, few studies
528 employ methods that enable precise measurements of these parameters, particularly with
529 regard to regional variation in liver shape and size. In the present study we observed that
530 decline in the liver S2S distances were associated with increasing age. This is in agreement
531 with previous observations, by ourselves and others, that overall liver volume decreases with
532 age [9, 41, 47]. However, there are some ultrasound reports suggesting liver size increases
533 with age [44]. This discrepancy may relate to variations in methodology since ultrasound
534 measurements of liver diameter may not reflect overall changes in liver volume. This clearly
535 reinforces the importance of absolute volumetric measurements, which, when combined with
536 statistical parametric mapping, enables simultaneous extraction of global and local changes.

537

538 Additionally, we found a strong and distinct regionality in liver morphometry which was
539 associated with body composition and liver PDFF. Specifically, we found that higher BMI and
540 WHR were strongly associated with positive S2S distance, in line with others who have
541 reported a positive correlation between liver size and anthropometric variables [45, 46]. We
542 also found that higher liver PDFF was significantly associated with positive S2S distances,
543 suggesting that hepatic fat is associated with both liver size and shape, with some clear
544 regional variations. We further explored whether the time of day the participants were scanned
545 was associated with S2S distances, given we have previously shown this to be associated
546 with fluctuations in liver volume [9]. However, we did not find a measurable effect.

547

548 We investigated whether conditions with known involvement of hepatic function had
549 discernible effects on our S2S measurements. For this we selected T2D, commonly

550 associated with increased deposition of liver PDFF, and subjects with known liver conditions,
551 which we expected to be associated with a more adverse phenotype. We found that T2D was
552 associated with outward shape variations in the liver after adjusting for PDFF, suggesting that
553 T2D affects liver morphology. It is well recognised that T2D is associated with a range of liver
554 conditions, with the prevalence of NAFLD in patients with T2D reported to be 55% and NASH
555 37.3% [48], substantially higher than the proportion of individuals in the general population
556 with NAFLD (19.9%) [3] or NASH (2.2%) [49]. Given the clinical heterogeneity of our current
557 T2D cohort, in terms of time of diagnosis and medication, as well as the possibility of collider
558 bias or reverse confounding, it is impossible to identify causal mechanisms for the observed
559 variation in S2S distances. Interestingly when we considered the interaction between age and
560 disease, we found no statistically significant interaction for liver disease, but there was a
561 significant interaction between age and the presence of T2D. We also considered whether the
562 interaction between disease and the presence of liver PDFF was associated with S2S
563 distances. Moreover, the variations covered a larger proportion of the liver in T2D compared
564 with liver disease. This may suggest that the hepatic tissue in T2D retains its overall relative
565 plasticity (i.e. less fibrotic-cirrhotic tissue), while in liver disease there may be regions that
566 have reduced capacity to accumulate fat or lost their plasticity and thus be less responsive to
567 geometrical changes. Further work is needed to determine how these changes may be utilised
568 to improve diagnosis or monitoring of disease progression. Future work in patients with biopsy-
569 characterised hepatic tissue should help to shed light on the heterogeneity of response to the
570 interaction between liver fat accumulation and liver health status.

571

572 We further identified regional variations in liver morphometry that are associated with
573 liver disease. Specifically, we observed an inward shape variation at the anterior part of the
574 right lobe, and posterior parts of the left and right lobes accompanied by an outward increase
575 in liver S2S distances in the anterior part of the left lobe in participants diagnosed with liver
576 disease. Previous studies have suggested that statistical shape modelling is a viable approach
577 for enhancing the understanding of the liver shape variations linked to the stage fibrosis and

578 even predicting it [13, 50]. With limited outcome and longitudinal data in the current study, the
579 clinical significance of these changes, particularly the simultaneous regional inward and
580 outward deformations in S2S distances are unclear. However, histological and radiological
581 studies of the liver in patients with cirrhosis have shown that the degree of volume reduction
582 and fibrosis is greater in the right lobe compared to the caudate lobe (which reportedly
583 expands) [51]. This suggests regional changes in S2S distances may reflect physiological
584 processes in the liver. It is well established that many diseases do not progress uniformly
585 across the liver, with differences reported within different zones (periportal, mid-lobular and
586 pericentral) of the liver lobule, which may reflect populations, different cell types, metabolic
587 function and differences in blood flow [52]. Whilst it is premature to adjudicate a mechanism
588 responsible for the changes described in the current study, the regional shape differences
589 associated to both AST:ALT and FIB-4, hinting at hepatocellular changes underpinning the
590 variation in S2S distances.

591

592 We assessed the predictive performance using shape features derived from the S2S
593 distances on the case-control cohorts with liver disease and T2D. We aim to determine
594 whether these shape features can add to prediction of disease beyond those obtained using
595 conventional volumetric measurements. We demonstrated that the model using the shape
596 features of the S2S distances improved the prediction of liver disease, however, there was no
597 improvement in T2D compared to the model with liver volume. Our methods using the shape
598 features, particularly in which histology is available, may provide additional information to
599 confirm the utility of our approach in monitoring disease and potentially predicting outcomes.
600 This in turn would open up the possibility of applying this methodology, in conjunction with
601 other techniques to determine and predict the overall trajectory of progression of disease and
602 identify those subjects requiring closer monitoring and more aggressive forms of treatment.
603 Future work is also needed to explore variations in liver morphometry by condensing the entire
604 coordinate matrix or deformation matrix into most distinct principal component modes to

605 categorise population variations, which could be used in genetic association studies to
606 enhance our understanding of chronic liver disease [17, 53].

607

608 Our study was not without limitations. To ensure sufficient numbers of participants in
609 the liver disease group, we included all participants in the imaging cohort who had a diagnosis
610 of liver disease, regardless of aetiology (alcoholic, toxic and inflammatory liver disease,
611 hepatitis, fibrosis and cirrhosis). This precludes us from a more in-depth granular analysis,
612 although our data does suggest that hepatocellular damage, particularly in more advanced
613 disease stages, resulted in significant S2S changes across the liver. Variation in disease
614 aetiology, the point of disease progression and the impact of on-going treatment may further
615 confound the interpretation of our observations in the liver disease cohort. Furthermore, this
616 study has only 3,088 follow-up data since the imaging visit, which limits the identification of
617 more severe cases and may limit the predictive power. Additional longitudinal measurements
618 will need to be required to assess age-related changes in disease cohorts.

619

620 **Conclusion**

621

622 This study demonstrates that methods to assess changes in liver morphology, beyond
623 simplistic volumetric analysis, can be applied at scale. In a population-based study we show
624 that inter- and intra-subjects' morphometric variations are associated with age, body
625 composition and liver phenotypes, as well as disease. Moreover, morphometric scores were
626 shown to improve the prediction of liver disease over-and-above conventional measures of
627 liver volume. The approach developed here will allow large-scale studies of patient-based
628 cohorts, enable disease-specific changes in morphology to be defined and tracked during both
629 progression and remission and facilitate disease prediction and stratification.

630

631 **Declarations**

632

633 **Competing interests**

634 M.C. and E.P.S. are employees of Calico Life Sciences LLC. M.T., N.B., B.W., J.D.B. and
635 E.L.T. declare no competing interests.

636

637 **Ethics approval and consent to participate**

638 The data resources used in this study have approval from ethics committees. Full anonymised
639 images and participants metadata from the UK Biobank cohort was obtained through UK
640 Biobank Access Application number 44584. The UK Biobank has approval from the North
641 West Multi-Centre Research Ethics Committee (REC reference: 11/NW/0382), and obtained
642 written informed consent from all participants prior to the study. All methods were performed
643 in accordance with the relevant guidelines and regulations as presented by the relevant
644 authorities, including the Declaration of Helsinki [https://www.ukbiobank.ac.uk/learn-more-
645 about-uk-biobank/about-us/ethics](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics) .

646

647 **Consent for publication**

648 Not applicable.

649

650 **Availability of data and materials**

651 The data that support the findings of this study are available from the UK Biobank
652 (<https://www.ukbiobank.ac.uk>), but restrictions apply to the availability of these data, which
653 were used under license for the current study, and so are not publicly available. Data are
654 however returned by us to the UK Biobank where they will be fully available on request.

655

656 **Funding**

657 This study was funded by Calico Life Sciences LLC, who provided the financial means to allow
658 authors to carry out the study. The funding bodies played no role in the design of the study and
659 collection, analysis, and interpretation of the data and the writing of the manuscript.

660

661 **Authors' contributions**

662 J.D.B., E.L.T., M.T. and M.C. conceived the study. J.D.B., B.W., E.L.T., N.B. and M.T.
663 designed the study. M.T., N.B., B.W., E.P.S. and M.C. implemented the methods and
664 performed the data analysis. M.T. defined the disease and physiological condition categories.
665 M.T. performed the image and statistical analysis. E.L.T., B.W., M.T., J.D.B., and N.B. drafted
666 the manuscript. All authors read and approved the manuscript.

667

668 **Acknowledgements**

669 This research has been conducted using the UK Biobank Resource under Application Number
670 44584.

671

672 **References**

673

674 1. Vos et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-
675 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*.
676 2020;396:1204–22.

677 2. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al.
678 Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of
679 hepatic steatosis in the general population. *Am J Physiol Endocrinol Metab*. 2005;288:E462–
680 8.

681 3. Wilman HR, Kelly M, Garratt S, Matthews PM, Milanese M, Herlihy A, et al. Characterisation
682 of liver fat in the UK Biobank cohort. *PLoS One*. 2017;12:e0172921.

683 4. Parisinos CA, Wilman HR, Thomas EL, Kelly M, Nicholls RC, McGonigle J, et al. Genome-
684 wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of
685 steatohepatitis. *J Hepatol*. 2020;73:241–51.

- 686 5. Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield JA, Hirschfield G, et al. Clinical
687 Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis
688 Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. *Clinical*
689 *Gastroenterology and Hepatology*. 2021.
- 690 6. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic
691 Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive
692 Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
693 *Gastroenterology*. 2017;152:598–607.e2.
- 694 7. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in
695 Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-
696 analysis of Paired-Biopsy Studies. *Clinical Gastroenterology and Hepatology*. 2015;13:643–
697 54.e9.
- 698 8. Asaturyan H, Thomas EL, Bell JD, Villarini B. A Framework for Automatic Morphological
699 Feature Extraction and Analysis of Abdominal Organs in MRI Volumes. *J Med Syst*.
700 2019;43:334.
- 701 9. Liu Y, Bastly N, Whitcher B, Bell JD, Sorokin EP, van Bruggen N, et al. Genetic architecture
702 of 11 organ traits derived from abdominal MRI using deep learning. *Elife*. 2021;10.
- 703 10. Penny WD, Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE. *Statistical Parametric*
704 *Mapping: The Analysis of Functional Brain Images*. Elsevier; 2011.
- 705 11. Ramezani M, Johnsrude I, Rasouljan A, Bosma R, Tong R, Hollenstein T, et al. Temporal-
706 lobe morphology differs between healthy adolescents and those with early-onset of
707 depression. *NeuroImage: Clinical*. 2014;6:145–55.
- 708 12. Nakao M, Nakamura M, Mizowaki T, Matsuda T. Statistical deformation reconstruction
709 using multi-organ shape features for pancreatic cancer localization. *Med Image Anal*.
710 2021;67:101829.

- 711 13. Hori M, Okada T, Higashiura K, Sato Y, Chen Y-W, Kim T, et al. Quantitative Imaging.
712 Academic Radiology. 2015;22:303–9.
- 713 14. Biffi C, de Marvao A, Attard MI, Dawes TJW, Whiffin N, Bai W, et al. Three-dimensional
714 cardiovascular imaging-genetics: a mass univariate framework. *Bioinformatics*. 2018;34:97–
715 103.
- 716 15. Jia S, Nivet H, Harrison J, Pennec X, Camaioni C, Jaïs P, et al. Left atrial shape is
717 independent predictor of arrhythmia recurrence after catheter ablation for atrial fibrillation: A
718 shape statistics study. *Heart Rhythm O2*. 2021;2 6Part A:622–32.
- 719 16. Marvao A de, de Marvao A, McGurk KA, Zheng SL, Thanaj M, Bai W, et al. Phenotypic
720 Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic
721 Cardiomyopathy. *Journal of the American College of Cardiology*. 2021;78:1097–110.
- 722 17. Smith SM, Elliott LT, Alfaro-Almagro F, McCarthy P, Nichols TE, Douaud G, et al. Brain
723 aging comprises many modes of structural and functional change with distinct genetic and
724 biophysical associations. *Elife*. 2020;9.
- 725 18. Wang X, Vrtiska TJ, Avula RT, Walters LR, Chakkera HA, Kremers WK, et al. Age, kidney
726 function, and risk factors associate differently with cortical and medullary volumes of the
727 kidney. *Kidney Int*. 2014;85:677–85.
- 728 19. Fitzpatrick JA, Kim JU, Cobbold JFL, McPhail MJW, Crossey MME, Bak-Bol AA, et al.
729 Changes in Liver Volume in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy.
730 *J Clin Exp Hepatol*. 2016;6:15–20.
- 731 20. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open
732 access resource for identifying the causes of a wide range of complex diseases of middle and
733 old age. *PLoS Med*. 2015;12:e1001779.
- 734 21. Littlejohns TJ, Holliday J, Gibson LM, Garratt S, Oesingmann N, Alfaro-Almagro F, et al.

- 735 The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection,
736 management and future directions. *Nature Communications*. 2020;11.
- 737 22. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. *Am Fam Physician*.
738 2006;73:1961–8.
- 739 23. Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. *BMJ*. 2014;349:g4596.
- 740 24. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of
741 a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
742 *Hepatology*. 2006;43:1317–25.
- 743 25. Yang G, Zhou S, Bozek J, Dong H-M, Han M, Zuo X-N, et al. Sample sizes and population
744 differences in brain template construction. *Neuroimage*. 2020;206:116318.
- 745 26. Witcher B, Thanaj M, Cule M, Liu Y, Basty N, Sorokin EP, et al. Precision MRI
746 phenotyping enables detection of small changes in body composition for longitudinal cohorts.
747 *Sci Rep*. 2022;12:3748.
- 748 27. Mamouris P, Nassiri V, Molenberghs G, van den Akker M, van der Meer J, Vaes B. Fast
749 and optimal algorithm for case-control matching using registry data: application on the
750 antibiotics use of colorectal cancer patients. *BMC Medical Research Methodology*. 2021;21.
- 751 28. Thanaj M, Basty N, Liu Y, Cule M, Sorokin EP, Louise Thomas E, et al. Mass Univariate
752 Regression Analysis for Three-Dimensional Liver Image-Derived Phenotypes. *Medical Image*
753 *Understanding and Analysis*. 2021;:165–76.
- 754 29. Bai W, Shi W, de Marvao A, Dawes TJW, O'Regan DP, Cook SA, et al. A bi-ventricular
755 cardiac atlas built from 1000 high resolution MR images of healthy subjects and an analysis
756 of shape and motion. *Medical Image Analysis*. 2015;26:133–45.
- 757 30. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration
758 with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain.

- 759 Med Image Anal. 2008;12:26–41.
- 760 31. Avants BB, Yushkevich P, Pluta J, Minkoff D, Korczykowski M, Detre J, et al. The optimal
761 template effect in hippocampus studies of diseased populations. *Neuroimage*. 2010;49:2457–
762 66.
- 763 32. Duan J, Bello G, Schlemper J, Bai W, Dawes TJW, Biffi C, et al. Automatic 3D Bi-
764 Ventricular Segmentation of Cardiac Images by a Shape-Refined Multi- Task Deep Learning
765 Approach. *IEEE Trans Med Imaging*. 2019;38:2151–64.
- 766 33. Smith S, Nichols T. Threshold-free cluster enhancement: Addressing problems of
767 smoothing, threshold dependence and localisation in cluster inference. *NeuroImage*.
768 2009;44:83–98.
- 769 34. Biffi et al. 2017. Biffi C. An introduction to mass univariate analysis of three-dimensional
770 phenotypes, <https://github.com/UK-Digital-Heart-Project/mutools3D>, R package version 1.0
771 (2017).
- 772 35. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
773 Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B*
774 (Methodological). 1995;57:289–300.
- 775 36. Erichson et al. 2017. Erichson BN, Zheng P, Aravkin S. Sparse principal component
776 analysis (SPCA), <https://github.com/erichson/spca>, R package version 0.1.2. 2018.
- 777 37. Kuhn et al. 2021. Kuhn M., Wing J., Weston S. et al.: Classification and Regression
778 Training, <https://github.com/topepo/caret/>, R package version 6.0-9.0 (2021).
- 779 38. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more
780 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*.
781 1988;44:837–45.
- 782 39. DeLand FH, North WA. Relationship between liver size and body size. *Radiology*.

- 783 1968;91:1195–8.
- 784 40. Heymsfield SB, Olafson RP, Kutner MH, Nixon DW. A radiographic method of quantifying
785 protein-calorie undernutrition. *The American Journal of Clinical Nutrition*. 1979;32:693–702.
- 786 41. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of
787 age upon liver volume and apparent liver blood flow in healthy man. *Hepatology*. 1989;9:297–
788 301.
- 789 42. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from
790 birth to adulthood: a meta-analysis. *Liver Transpl*. 2005;11:1481–93.
- 791 43. Yanaga K, Honda H, Ikeda Y, Nishizaki AT, Yamamoto K, Sugimachi K. Significance of
792 Liver Size in Hepatic Surgery. *HPB Surgery*. 1997;10:195–200.
- 793 44. Kratzer W, Fritz V, Mason RA, Haenle MM, Kaechele V, Roemerstein Study Group.
794 Factors Affecting Liver Size. *Journal of Ultrasound in Medicine*. 2003;22:1155–61.
- 795 45. Patzak M, Porzner M, Oeztuerk S, Mason RA, Wilhelm M, Graeter T, et al. Assessment of
796 liver size by ultrasonography. *J Clin Ultrasound*. 2014;42:399–404.
- 797 46. Kromrey ML, Ittermann T, vWahsen C, Plodeck V, Seppelt D, Hoffmann RT, et al.
798 Reference values of liver volume in Caucasian population and factors influencing liver size.
799 *Eur J Radiol*. 2018;106:32–7.
- 800 47. Marchesini G, Bua V, Brunori A, Bianchi G, Pisi P, Fabbri A, et al. Galactose elimination
801 capacity and liver volume in aging man. *Hepatology*. 1988;8:1079–83.
- 802 48. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global
803 epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and
804 meta-analysis. *J Hepatol*. 2019;71:793–801.
- 805 49. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The

806 economic and clinical burden of nonalcoholic fatty liver disease in the United States and
807 Europe. *Hepatology*. 2016;64:1577–86.

808 50. Soufi M, Otake Y, Hori M, Moriguchi K, Imai Y, Sawai Y, et al. Liver shape analysis using
809 partial least squares regression-based statistical shape model: application for understanding
810 and staging of liver fibrosis. *Int J Comput Assist Radiol Surg*. 2019;14:2083–93.

811 51. Harbin WP, Robert NJ, Ferrucci JT Jr. Diagnosis of cirrhosis based on regional changes
812 in hepatic morphology: a radiological and pathological analysis. *Radiology*. 1980;135:273–83.

813 52. Cunningham RP, Porat-Shliom N. Liver Zonation – Revisiting Old Questions With New
814 Technologies. *Frontiers in Physiology*. 2021;12.

815 53. Bonazzola R, Ravikumar N, Attar R, Ferrante E, Syeda-Mahmood T, Frangi AF. Image-
816 Derived Phenotype Extraction for Genetic Discovery via Unsupervised Deep Learning in CMR
817 Images. *Medical Image Computing and Computer Assisted Intervention – MICCAI 2021*.
818 2021;:699–708.